Kindred Biosciences, Inc., a biopharmaceutical company, focuses on the development of therapies for pets. The company's product pipeline includes small molecules and biologics for a range of indications in dogs, cats, and horses. Its lead product candidates comprise Zimeta, a dipyrone injection for the control of pyrexia (fever) in horses; and Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats. The company's other small molecule product candidates consist of KIND-014 for treatment of equine gastric ulcers in horses; and KIND-015 for the management of clinical signs related to equine metabolic syndrome. It is also developing biologics programs, including KIND-510, a feline recombinant erythropoietin for the control of non-regenerative anemia in cats; KIND-011, an anti-tumor necrosis factor (TNF) to treat newborn foals; and canine atopic dermatitis, an immune-mediated inflammatory, chronic skin disease related to allergies. In addition, the company engages in the development of other biologic product candidates, such as KIND-502 to treat allergic and immune-mediated diseases; KIND-0888, an antibody that targets CD20; various antibodies that target cytokines involved in atopic dermatitis; KIND-509, an antibody that targets the canine TNF; and KIND-Bodies, a biologics scaffold technology. Further, it is developing anti-IL31, anti-IL17, and anti-IL4/13 sink antibodies for treating atopic dermatitis in dogs; anti-TNF antibody for inflammatory bowel disease in dogs; anti-IgE antibody for treating allergic diseases in dogs; anti-VEGF antibody for cancer in dogs; anti-CD20 for treating cancer and autoimmune diseases in dogs; and checkpoint inhibitors to treat cancer in dogs. Kindred Biosciences, Inc. was founded in 2012 and is headquartered in Burlingame, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:KIN
CUSIPN/A
Phone650-701-7901
Debt
Debt-to-Equity RatioN/A
Current Ratio17.78
Quick Ratio17.78
Price-To-Earnings
Trailing P/E Ratio-11.95
Forward P/E Ratio-9.74
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.00 per share
Price / Book4.90
Profitability
EPS (Most Recent Fiscal Year)($1.23)
Net Income$-30,870,000.00
Net MarginsN/A
Return on Equity-42.03%
Return on Assets-39.85%
Miscellaneous
Employees63
Outstanding Shares33,800,000
Market Cap$486.72 million
Kindred Biosciences (NASDAQ:KIN) Frequently Asked Questions
What is Kindred Biosciences' stock symbol?
Kindred Biosciences trades on the NASDAQ under the ticker symbol "KIN."
How were Kindred Biosciences' earnings last quarter?
Kindred Biosciences Inc (NASDAQ:KIN) released its earnings results on Thursday, August, 9th. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing analysts' consensus estimates of ($0.38) by $0.01. View Kindred Biosciences' Earnings History.
When is Kindred Biosciences' next earnings date?
What price target have analysts set for KIN?
9 analysts have issued 1-year price objectives for Kindred Biosciences' shares. Their forecasts range from $16.00 to $20.00. On average, they expect Kindred Biosciences' share price to reach $17.1875 in the next year. This suggests a possible upside of 16.9% from the stock's current price. View Analyst Price Targets for Kindred Biosciences.
What is the consensus analysts' recommendation for Kindred Biosciences?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kindred Biosciences in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kindred Biosciences.
What are Wall Street analysts saying about Kindred Biosciences stock?
Here are some recent quotes from research analysts about Kindred Biosciences stock:
- 1. According to Zacks Investment Research, "Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company's strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes. " (8/15/2018)
- 2. Cantor Fitzgerald analysts commented, ". Post 2Q18, we reiterate our Overweight rating and a 12- month price target of $20. We believe KIN’s pipeline of novel animal health drugs will drive long-term shareholder value beyond levels currently reflected in the stock. As KIN advances its pipeline, investors should begin to appreciate the peak revenue potential of the products the company brings to market. Kindred has one approved product, Mirataz, and expects the approval of Zimeta IV later this year or early next year, with two approvals a year thereafter. We expect upward earnings revisions, multiple expansion, and pipeline advancements to drive the stock higher." (8/9/2018)
Who are some of Kindred Biosciences' key competitors?
Some companies that are related to Kindred Biosciences include Mirati Therapeutics (MRTX), G1 Therapeutics (GTHX), Pacira Pharmaceuticals (PCRX), Clovis Oncology (CLVS), Enanta Pharmaceuticals (ENTA), Arena Pharmaceuticals (ARNA), Zogenix (ZGNX), Nabriva Therapeutics (NBRV), Portola Pharmaceuticals (PTLA), Aimmune Therapeutics (AIMT), ACADIA Pharmaceuticals (ACAD), Insmed (INSM), Puma Biotechnology (PBYI), TESARO (TSRO) and Allakos (ALLK).
Who are Kindred Biosciences' key executives?
Kindred Biosciences' management team includes the folowing people:
- Dr. Richard Chin, Co-Founder, Pres, CEO & Director (Age 51)
- Ms. Denise M. Bevers, Co-Founder, COO & Sec. (Age 51)
- Ms. Wendy K. Wee, Chief Financial Officer (Age 65)
- Dr. Hangjun Zhan, Chief Scientific Officer (Age 58)
Has Kindred Biosciences been receiving favorable news coverage?
Press coverage about KIN stock has trended somewhat positive this week, according to Accern Sentiment Analysis. Accern ranks the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Kindred Biosciences earned a coverage optimism score of 0.10 on Accern's scale. They also gave media stories about the biopharmaceutical company an impact score of 46.56 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days. View Recent Headlines for Kindred Biosciences.
Who are Kindred Biosciences' major shareholders?
Kindred Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Ariel Investments LLC (7.87%), Dimensional Fund Advisors LP (4.77%), BlackRock Inc. (4.70%), Renaissance Technologies LLC (3.36%), General American Investors Co. Inc. (2.11%) and Granahan Investment Management Inc. MA (0.94%). Company insiders that own Kindred Biosciences stock include Park West Asset Management Llc, Raymond Townsend and Richard Chin. View Institutional Ownership Trends for Kindred Biosciences.
Which institutional investors are selling Kindred Biosciences stock?
KIN stock was sold by a variety of institutional investors in the last quarter, including B. Riley Financial Inc., Dimensional Fund Advisors LP, Bank of New York Mellon Corp, Connor Clark & Lunn Investment Management Ltd., NJ State Employees Deferred Compensation Plan and General American Investors Co. Inc.. Company insiders that have sold Kindred Biosciences company stock in the last year include Raymond Townsend and Richard Chin. View Insider Buying and Selling for Kindred Biosciences.
Which institutional investors are buying Kindred Biosciences stock?
KIN stock was acquired by a variety of institutional investors in the last quarter, including Ariel Investments LLC, Renaissance Technologies LLC, BlackRock Inc., Granahan Investment Management Inc. MA, Sit Investment Associates Inc., Trexquant Investment LP, Citadel Advisors LLC and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for Kindred Biosciences.
How do I buy shares of Kindred Biosciences?
Shares of KIN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Kindred Biosciences' stock price today?
One share of KIN stock can currently be purchased for approximately $14.70.
How big of a company is Kindred Biosciences?
Kindred Biosciences has a market capitalization of $486.72 million. The biopharmaceutical company earns $-30,870,000.00 in net income (profit) each year or ($1.23) on an earnings per share basis. Kindred Biosciences employs 63 workers across the globe.
How can I contact Kindred Biosciences?
Kindred Biosciences' mailing address is 1555 BAYSHORE HIGHWAY SUITE 200, BURLINGAME CA, 94010. The biopharmaceutical company can be reached via phone at 650-701-7901 or via email at [email protected]
MarketBeat Community Rating for Kindred Biosciences (NASDAQ KIN)
MarketBeat's community ratings are surveys of what our community members think about Kindred Biosciences and other stocks. Vote "Outperform" if you believe KIN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KIN will underperform the S&P 500 over the long term. You may vote once every thirty days.
